Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
3
60%
Ph phase_3
1
20%

Phase Distribution

0

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Other(3)

Detailed Status

unknown3
Completed2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (75.0%)
Phase 31 (25.0%)

Trials by Status

completed240%
unknown360%

Recent Activity

0 active trials
Showing 5 of 5
unknownphase_2

Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis

NCT05716035
unknownphase_2

Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)

NCT04317092
completed

COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU

NCT05302947
unknownphase_3

Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia

NCT04361032
completedphase_2

Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders

NCT03350633

Clinical Trials (5)

Showing 5 of 5 trials
NCT05716035Phase 2

Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis

Unknown
NCT04317092Phase 2

Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)

Unknown
NCT05302947

COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU

Completed
NCT04361032Phase 3

Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia

Unknown
NCT03350633Phase 2

Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5